Assignee
ARAXES PHARMA LLC
US·46 granted patents·13 pending applications·919 citations·filing 2014–2024
Top patents by PatentIndex Score
59 records- 0198US10144724B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Dec 4, 2018·44 cites·42 claims
- 0298US9810690B2Method for screening inhibitors of RasARAXES PHARMA LLC·Filed 2016·Granted Nov 7, 2017·41 cites·30 claims
- 0397US10745385B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2018·Granted Aug 18, 2020·17 cites·54 claims
- 0497US10646488B2Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted May 12, 2020·22 cites·16 claims
- 0597US10377743B2Inhibitors of RAS and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted Aug 13, 2019·29 cites·31 claims
- 0697US10370386B2Substituted quinolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2017·Granted Aug 6, 2019·33 cites·30 claims
- 0797US10351550B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 16, 2019·27 cites·32 claims
- 0897US10246424B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Apr 2, 2019·36 cites·90 claims
- 0997US9988357B2Methods for preparation of quinazoline derivativesARAXES PHARMA LLC·Filed 2016·Granted Jun 5, 2018·38 cites·32 claims
- 1097US9926267B2Covalent inhibitors of K-Ras G12CARAXES PHARMA LLC·Filed 2015·Granted Mar 27, 2018·38 cites·35 claims
- 1197US9862701B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2015·Granted Jan 9, 2018·45 cites·18 claims
- 1297US9840516B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2014·Granted Dec 12, 2017·73 cites·33 claims
- 1397US9745319B2Irreversible covalent inhibitors of the GTPase K-Ras G12CARAXES PHARMA LLC·Filed 2014·Granted Aug 29, 2017·43 cites·11 claims
- 1497US9227978B2Covalent inhibitors of Kras G12CARAXES PHARMA LLC·Filed 2014·Granted Jan 5, 2016·47 cites·24 claims
- 1596US10927125B2Substituted cinnolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 23, 2021·11 cites·29 claims
- 1696US10919850B2Covalent inhibitors of KRas G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 16, 2021·9 cites·38 claims
- 1796US10858343B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 8, 2020·11 cites·15 claims
- 1896US10829458B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Nov 10, 2020·13 cites·29 claims
- 1996US10730867B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Aug 4, 2020·15 cites·19 claims
- 2096US10723738B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2019·Granted Jul 28, 2020·15 cites·22 claims
- 2196US10689356B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jun 23, 2020·16 cites·15 claims
- 2296US10414757B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Sep 17, 2019·33 cites·49 claims
- 2396US10280172B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2017·Granted May 7, 2019·34 cites·19 claims
- 2496US10273207B2Covalent inhibitors of kras G12CARAXES PHARMA LLC·Filed 2018·Granted Apr 30, 2019·24 cites·34 claims
- 2595US10736897B2Compounds and methods of use thereof for treatment of cancerARAXES PHARMA LLC·Filed 2018·Granted Aug 11, 2020·28 cites·15 claims
- 2695US10428064B2Fused-tricyclic inhibitors of KRAS and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Oct 1, 2019·27 cites·28 claims
- 2795US10111874B2Combination therapies for treatment of cancerARAXES PHARMA LLC·Filed 2015·Granted Oct 30, 2018·39 cites·20 claims
- 2895US10011600B2Methods and compositions for inhibition of RasARAXES PHARMA LLC·Filed 2015·Granted Jul 3, 2018·12 cites·21 claims
- 2994US11878985B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2020·Granted Jan 23, 2024·2 cites·43 claims
- 3094US11377441B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2020·Granted Jul 5, 2022·3 cites·28 claims
- 3194US11021470B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Jun 1, 2021·8 cites·21 claims
- 3294US10882847B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jan 5, 2021·11 cites·23 claims
- 3394US10875842B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 29, 2020·11 cites·20 claims
- 3493US11059819B2Fused hetero-hetero bicyclic compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 13, 2021·8 cites·20 claims
- 3593US10975071B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Apr 13, 2021·9 cites·20 claims
- 3693US10822312B2Substituted quinazoline compounds and methods of useARAXES PHARMA LLC·Filed 2017·Granted Nov 3, 2020·10 cites·12 claims
- 3793US10647703B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted May 12, 2020·18 cites·13 claims
- 3889US11279689B21-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancerARAXES PHARMA LLC·Filed 2018·Granted Mar 22, 2022·4 cites·13 claims
- 3989US11136308B2Substituted quinazoline and quinazolinone compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Oct 5, 2021·5 cites·26 claims
- 4088US11274093B2Fused bicyclic benzoheteroaromatic compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Mar 15, 2022·4 cites·16 claims
- 4188US2024352028A1Substituted quinazolines as inhibitors of kras g12cARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 4287US11358959B2Benzothiophene and benzothiazole compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jun 14, 2022·4 cites·20 claims
- 4384US2025154133A1Covalent inhibitors of krasARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 4484US2024043441A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 4584US2023303586A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 4683USRE50527ECovalent inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2023·Granted Aug 12, 2025·0 cites·41 claims
- 4781US12234244B2Substituted piperazines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2022·Granted Feb 25, 2025·0 cites·12 claims
- 4880USRE50490ESubstituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2022·Granted Jul 15, 2025·0 cites·29 claims
- 4977US11639346B2Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRASARAXES PHARMA LLC·Filed 2018·Granted May 2, 2023·2 cites·25 claims
- 5076US2023203018A1Covalent inhibitors of krasARAXES PHARMA LLC·Filed 2022·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ARAXES PHARMA LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →